rs55964611

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_004700.4(KCNQ4):​c.1665G>A​(p.Pro555Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0366 in 1,613,944 control chromosomes in the GnomAD database, including 1,233 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.032 ( 122 hom., cov: 31)
Exomes 𝑓: 0.037 ( 1111 hom. )

Consequence

KCNQ4
NM_004700.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: -5.63
Variant links:
Genes affected
KCNQ4 (HGNC:6298): (potassium voltage-gated channel subfamily Q member 4) The protein encoded by this gene forms a potassium channel that is thought to play a critical role in the regulation of neuronal excitability, particularly in sensory cells of the cochlea. The current generated by this channel is inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. The encoded protein can form a homomultimeric potassium channel or possibly a heteromultimeric channel in association with the protein encoded by the KCNQ3 gene. Defects in this gene are a cause of nonsyndromic sensorineural deafness type 2 (DFNA2), an autosomal dominant form of progressive hearing loss. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 1-40835018-G-A is Benign according to our data. Variant chr1-40835018-G-A is described in ClinVar as [Benign]. Clinvar id is 45103.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-40835018-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-5.63 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0315 (4805/152320) while in subpopulation NFE AF= 0.0453 (3081/68026). AF 95% confidence interval is 0.044. There are 122 homozygotes in gnomad4. There are 2309 alleles in male gnomad4 subpopulation. Median coverage is 31. This position pass quality control queck.
BS2
High AC in GnomAd4 at 4805 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
KCNQ4NM_004700.4 linkc.1665G>A p.Pro555Pro synonymous_variant Exon 12 of 14 ENST00000347132.10 NP_004691.2 P56696-1B3KQH8

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
KCNQ4ENST00000347132.10 linkc.1665G>A p.Pro555Pro synonymous_variant Exon 12 of 14 1 NM_004700.4 ENSP00000262916.6 P56696-1
KCNQ4ENST00000509682.6 linkc.1503G>A p.Pro501Pro synonymous_variant Exon 11 of 13 5 ENSP00000423756.2 P56696-2
KCNQ4ENST00000443478.3 linkc.1245G>A p.Pro415Pro synonymous_variant Exon 11 of 13 5 ENSP00000406735.3 H0Y6N7
KCNQ4ENST00000506017.1 linkn.984G>A non_coding_transcript_exon_variant Exon 9 of 11 2

Frequencies

GnomAD3 genomes
AF:
0.0315
AC:
4801
AN:
152202
Hom.:
121
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0132
Gnomad AMI
AF:
0.0669
Gnomad AMR
AF:
0.0189
Gnomad ASJ
AF:
0.0164
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00827
Gnomad FIN
AF:
0.0624
Gnomad MID
AF:
0.0127
Gnomad NFE
AF:
0.0453
Gnomad OTH
AF:
0.0287
GnomAD3 exomes
AF:
0.0301
AC:
7569
AN:
251452
Hom.:
181
AF XY:
0.0304
AC XY:
4131
AN XY:
135916
show subpopulations
Gnomad AFR exome
AF:
0.0119
Gnomad AMR exome
AF:
0.0141
Gnomad ASJ exome
AF:
0.0154
Gnomad EAS exome
AF:
0.000163
Gnomad SAS exome
AF:
0.00921
Gnomad FIN exome
AF:
0.0572
Gnomad NFE exome
AF:
0.0441
Gnomad OTH exome
AF:
0.0315
GnomAD4 exome
AF:
0.0371
AC:
54282
AN:
1461624
Hom.:
1111
Cov.:
31
AF XY:
0.0364
AC XY:
26464
AN XY:
727118
show subpopulations
Gnomad4 AFR exome
AF:
0.0130
Gnomad4 AMR exome
AF:
0.0157
Gnomad4 ASJ exome
AF:
0.0167
Gnomad4 EAS exome
AF:
0.0000756
Gnomad4 SAS exome
AF:
0.00914
Gnomad4 FIN exome
AF:
0.0578
Gnomad4 NFE exome
AF:
0.0421
Gnomad4 OTH exome
AF:
0.0324
GnomAD4 genome
AF:
0.0315
AC:
4805
AN:
152320
Hom.:
122
Cov.:
31
AF XY:
0.0310
AC XY:
2309
AN XY:
74480
show subpopulations
Gnomad4 AFR
AF:
0.0133
Gnomad4 AMR
AF:
0.0188
Gnomad4 ASJ
AF:
0.0164
Gnomad4 EAS
AF:
0.000193
Gnomad4 SAS
AF:
0.00828
Gnomad4 FIN
AF:
0.0624
Gnomad4 NFE
AF:
0.0453
Gnomad4 OTH
AF:
0.0284
Alfa
AF:
0.0312
Hom.:
34
Bravo
AF:
0.0283
Asia WGS
AF:
0.00462
AC:
16
AN:
3478
EpiCase
AF:
0.0403
EpiControl
AF:
0.0406

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:5
Sep 08, 2017
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 07, 2012
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Pro555Pro in Exon 12 of KCNQ4: This variant is not expected to have clinical si gnificance because it does not alter an amino acid residue, is not located withi n the splice consensus sequence, and has been identified in 3.9% (276/7020) of E uropean American chromosomes from a broad population by the NHLBI Exome Sequenci ng Project (http://evs.gs.washington.edu/EVS; dbSNP rs55964611). -

not provided Benign:3
Nov 09, 2018
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Autosomal dominant nonsyndromic hearing loss 2A Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.83
CADD
Benign
0.20
DANN
Benign
0.77

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs55964611; hg19: chr1-41300690; COSMIC: COSV61273121; API